01 1Chongqing Sintaho Pharmaceutical
01 1ERIBULIN MESYLATE
01 1China
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-09-22
DMF Number : 37559
Submission : 2023-01-31
Status : Active
Type : II
20
Chongqing Sintaho Pharmaceutical Co Ltd, based in China, is a pharmaceutical company.
They are recognized for Chongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.
One of their notable products is ERIBULIN MESYLATE, with a corresponding US DMF Number 37559.
Remarkably, this DMF maintains an Active status since its submission on January 31, 2023, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 13, 2023, and payment made on September 22, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II
